The randomized, placebo-controlled study will recruit about 100 people with newly diagnosed Parkinson’s disease at sites across Europe. It will evaluate the efficacy, safety and tolerability of HER-096 and explore digital biomarkers that may detect treatment effects and disease progression more sensitively. The study includes a 36-week double-blind period, followed by 24 weeks in which all participants receive active treatment.

Karolinska University Hospital coordinates the consortium, and Herantis is the sponsor of the study and leads its scientific and technical work. Luxembourg Institute of Health leads clinical study activities together with Centre Hospitalier de Luxembourg. Karolinska University Hospital and Skåne University Hospital are clinical sites, and Karolinska Institutet contributes expertise in brain imaging. Herantis is targeting a clinical trial application in the fourth quarter of 2026, with first participant dosing expected in the first half of 2027, subject to financing and regulatory approvals.

“We are pleased to launch HERMOD and begin the next stage in the clinical development of HER-096. This project will help us evaluate the potential of HER-096 in people with Parkinson’s disease and generate important evidence to support future development decisions,” says Antti Vuolanto, CEO of Herantis Pharma.